{"schema_version":"secwatch.filing_event.v1","accession":"0001663577-24-000143","form_type":"8-K","ticker":"SKVI","cik":"0001085277","company_name":"SKINVISIBLE, INC.","filed_at":"2024-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.226764+00:00","generated_at":"2026-06-01T07:35:38.512725+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Skinvisible files provisional patent for transdermal obesity drug delivery using Invisicare","bullets":["Provisional patent filed for transdermal composition of CB-1 receptor antagonists and/or GLP-1 receptor agonists.","Uses proprietary Invisicare technology; studies show up to 10x increase in transdermal delivery effectiveness.","Aims to offer needle-free alternative to injections for obesity drugs; potential to improve compliance.","Global obesity drug market projected to exceed $30B by 2027.","Company actively seeking strategic partnerships for development."],"urls":{"canonical":"https://secwatch.observer/filing/0001663577-24-000143","json":"https://secwatch.observer/filing/0001663577-24-000143.json","markdown":"https://secwatch.observer/filing/0001663577-24-000143.md","text":"https://secwatch.observer/filing/0001663577-24-000143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1085277/000166357724000143/0001663577-24-000143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1085277/000166357724000143/skvi8k052924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:35:38.512725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}